GATM gene variants and statin myopathy risk

Nature

Volumn 513, Issue 7518, 2014, Pages E1-

  Carr, D F ^a   Alfirevic, A ^a   Johnson, R ^a   Chinoy, H ^b   Van Staa, T ^b   Pirmohamed, M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; AMIDINOTRANSFERASE;

DISEASE INCIDENCE; ENZYME ACTIVITY; GENE EXPRESSION; GENOTYPE; MUSCLE;

ARTICLE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLYCINE AMIDINOTRANSFERASE GENE; HUMAN; MYOPATHY; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MUSCLE DISEASE; NOTE; QUANTITATIVE TRAIT LOCUS;

AMIDINOTRANSFERASES; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; QUANTITATIVE TRAIT LOCI; SIMVASTATIN;

EID: 84907787759     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13628     Document Type: Article

References (4)

1. Mangravite, L. M. et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 502, 377-380 (2013).(WARNING)
2. O'Meara, H. et al. Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the clinical practice research datalink. Br. J. Clin. Pharmacol. 77, 831-838 (2014).(WARNING)
3. Carr, D. F. et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin. Pharmacol. Ther. 94, 695-701 (2013).(WARNING)
4. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).(WARNING)